{"product_id":"michigan-medicine-advanced-genitourinary-malignancies-symposium-2025","title":"Michigan Medicine Advanced Genitourinary Malignancies Symposium 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: Physicians (Medical Oncologists, Urologists, Radiation Oncologists, Internists)\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis one-day symposium is dedicated to the comprehensive management of genitourinary malignancies, including prostate, bladder, and kidney cancers. Hosted by the NCI-designated Rogel Cancer Center, the course emphasizes a transdisciplinary approach to reducing the cancer burden and advancing health equity. It serves as a critical update for clinicians, bridging the gap between cutting-edge research—such as novel biomarkers and cellular therapies—and standard clinical practice. The program highlights the University of Michigan’s role in leading groundbreaking clinical trials and refining standards of care for complex GU cases.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWhat You Will Learn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eAttendees will be able to:\u003c\/h3\u003e\n\u003cp\u003eUnderstand and apply the latest diagnostic modalities for the classification and risk-stratification of genitourinary cancers.\u003c\/p\u003e\n\u003cp\u003eAppreciate the rapidly evolving therapeutic landscape, specifically the increasing use of targeted agents, immunomodulators, antibody-drug conjugates (ADCs), and cellular therapies.\u003c\/p\u003e\n\u003cp\u003eIdentify impactful research findings that drive future diagnostic and prognostic strategies.\u003c\/p\u003e\n\u003cp\u003eNavigate clinical nuances in managing “in-between” cases, such as localized prostate cancer with nodal PSMA avidity.\u003c\/p\u003e\n\u003cp\u003eEvaluate the role of circulating tumor DNA (ctDNA) in risk-stratifying patients with Muscle-Invasive Bladder Cancer (MIBC).\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eEvent Details\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDate: Saturday, November 22, 2025\u003c\/p\u003e\n\u003cp\u003eLocation: The Sheraton Ann Arbor, 3200 Boardwalk Dr, Ann Arbor, Michigan\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWho Should Attend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eThis course is designed for the interdisciplinary team involved in GU oncology:\u003c\/h3\u003e\n\u003cp\u003ePhysicians (Medical Oncologists, Urologists, Radiation Oncologists, Internists)\u003c\/p\u003e\n\u003cp\u003eHouse Officers (Residents and Fellows)\u003c\/p\u003e\n\u003cp\u003ePhysician Assistants and Nurse Practitioners\u003c\/p\u003e\n\u003cp\u003eNurses\u003c\/p\u003e\n\u003cp\u003eOther Healthcare Professionals involved in cancer care\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWhy Attend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eEmerging Therapies: Gain specific insights into the “nuance” of using Antibody-Drug Conjugates (ADCs) in bladder cancer, moving beyond simple prescription to understanding toxicity and sequencing.\u003c\/p\u003e\n\u003cp\u003ePrecision Medicine: Learn how new tools like PSMA PET and ctDNA are redefining “localized” versus “metastatic” disease, directly impacting treatment decisions for prostate and bladder cancer patients.\u003c\/p\u003e\n\u003cp\u003eExpert Faculty: Hear directly from Michigan Medicine leaders who are driving the research on SBRT for renal cell carcinoma and immunotherapy strategies.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eImmunotherapy for Localized Bladder Cancer – Universal Strategy or Tailored Approach\u003c\/p\u003e\n\u003cp\u003eRisk Stratification in MIBC – The Emerging Role of ctDNA\u003c\/p\u003e\n\u003cp\u003eFrom Targets to Toxicity – Clinical Nuance in ADC Therapy for Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eMetastatic Body Radiotherapy for Localized RCC – Emerging Evidence, Evolving Role\u003c\/p\u003e\n\u003cp\u003eChoosing Wisely – Patient Selection for Adjuvant IO in Kidney Cancer\u003c\/p\u003e\n\u003cp\u003eMetastatic RCC with Bulky Primary – Navigating the Balance Between Local and Systemic Therapy (Sarah Elizabeth Yentz, MD)\u003c\/p\u003e\n\u003cp\u003eMetastatic RCC with Bulky Primary – Navigating the Balance Between Local and Systemic Therapy (Udit Singhal, MD)\u003c\/p\u003e\n\u003cp\u003eManaging the ‘In-Between’ – Localized Prostate Cancer with Nodal PSMA Avidity\u003c\/p\u003e\n\u003cp\u003eWhen to Scan and What to Use – Imaging the Biochemically Recurrent Prostate Cancer Patient\u003c\/p\u003e\n\u003cp\u003eWhen to Scan and What to Use – Imaging the Biochemically Recurrent Prostate Cancer Patient\u003c\/p\u003e\n\u003cp\u003eWhen to Radiate – Managing the Primary and Metastases in Low-Volume Metastatic Castrate Sensitive Prostate Cancer\u003c\/p\u003e\n\u003cp\u003eTailoring Systemic Treatment in Low-volume mCSPC – How Long and What to Choose\u003c\/p\u003e\n\u003cp\u003eTo PET or Not – Deciding the Best Imaging for Metastatic Prostate Cancer\u003c\/p\u003e\n\u003cp\u003ePluvicto and Docetaxel in Metastatic Castrate Resistant Prostate Cancer – Making the Right Choice for Your Patient (Sarah Elizabeth Yentz, MD)\u003c\/p\u003e\n\u003cp\u003ePluvicto and Docetaxel in Metastatic Castrate Resistant Prostate Cancer – Making the Right Choice for Your Patient (Sean R. Miller, MD)\u003c\/p\u003e\n\u003cp\u003eBeyond Symptom Control The Evolving Role of Radiation in Metastatic Castrate Resistant Prostate Cancer\u003c\/p\u003e\n\u003cp\u003eGermline Testing in Prostate Cancer What the Oncologist Needs to Know\u003c\/p\u003e\n\u003cp\u003eNext Generation Sequencing in Metastatic Prostate Cancer When, Who, and Why\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405805670596,"sku":null,"price":32.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Michigan-Medicine-Advanced-Genitourinary-Malignancies-Symposium-2025.jpg?v=1784216473","url":"https:\/\/medicalcoursespro.com\/products\/michigan-medicine-advanced-genitourinary-malignancies-symposium-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}